David Ambinder, MD

David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.

Articles by David Ambinder, MD

Guru P. Sonpavde, MDAdvanced Urothelial Carcinoma | May 20, 2024
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
View More
David Ambinder, MDProstate Cancer | March 29, 2024
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
David Ambinder, MDUrothelial Carcinoma | May 20, 2024
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
David Ambinder, MDLocalized | December 4, 2023
Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.
David Ambinder, MDSUO 2023 | November 27, 2023
The SUO meeting pays special attention to patients who responded well to NAC, the BCG shortage, trimodal therapy, and more.
David Ambinder, MDNon-Muscle Invasive Urothelial Carcinoma | October 30, 2023
Is there a better way to manage low-grade NMIBC? Adding UGN-102 to the current standard of care may be the answer.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | October 30, 2023
From presentation with a testicular mass to treatment options, this provides valuable insights for community oncologists.
Aditya Bagrodia, MD, FACSTesticular, Penile, and Rare Malignancies | October 6, 2023
Drs. Bagrodia and Ambinder provide an overview of the care continuum for newly diagnosed testicular cancer patients.
Aditya Bagrodia, MD, FACSTesticular, Penile, and Rare Malignancies | October 6, 2023
Drs. Bagrodia and Ambinder walk through a community urologist's approach to a patient who presents with a testicular mass.
David Ambinder, MDUrothelial Carcinoma | October 2, 2023
A recent study adds to the scant literature on preclinical bladder autotransplantation before a first-in-human trial.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
Unique characteristics include higher stage at presentation and a more aggressive subsequent clinical course.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
It may be time to include RPLND for patients with retroperitoneal disease following treatment for seminoma.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | August 15, 2023
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 28, 2023
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 24, 2023
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Katie S. Murray, DO, MSUpper Tract Urothelial Carcinoma | July 24, 2023
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Katie S. Murray, DO, MSUpper Tract Urothelial Carcinoma | July 24, 2023
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
David Ambinder, MDUpper Tract Urothelial Carcinoma | June 28, 2023
The recently released AUA/SUO guideline on UTUC includes 6 guidelines on neoadjuvant/adjuvant chemotherapy and immunotherapy.